Older pills often safer; many think new is better

September 12, 2011 By CARLA K. JOHNSON , AP Medical Writer in Medications

Many consumers mistakenly believe new prescription drugs are always safer than those with long track records, and that only extremely effective drugs without major side effects win government approval, according to a new study.

A of nearly 3,000 adults finds that about 4 in 10 wrongly believe the U.S. approves only "extremely effective" drugs. One in 4 mistakenly believes the FDA allows only drugs that don't have serious side effects.

That means consumers "may not get the benefit from drugs they think they're getting, or they may expose themselves to more harm than they think" said study co-author Dr. Steven Woloshin of the Dartmouth Institute for and Clinical Practice and the VA Outcomes Group

In truth, the FDA approves a new when its benefits outweigh any known risks. doesn't mean the drug's benefits are large compared to drugs already on the market. And risks for some drugs appear only after they've been used by millions of people and long after FDA approval. For instance, & Co. withdrew the FDA-approved arthritis pill Vioxx after its heart risks surfaced.

The new survey, appearing in Monday's Archives of Internal Medicine, revealed a partial solution to consumer confusion: Simply worded cautions can make a difference in which drugs people choose.

To test that idea, the researchers dreamed up two fictional drugs for heart disease and two for heartburn. The survey posed a question: Which drug would you choose?

Participants were told both heart disease drugs were free and both lowered cholesterol, but only one was known to reduce heart attacks.

Seventy-one percent of people chose the better drug that reduced heart attacks, when they were reminded in a warning the other one only lowered cholesterol levels. "It is not known whether it will help patients feel better or live longer," the warning said. Fewer people, 59 percent, made the better choice when they weren't given the added caution.

The make-believe heartburn drugs worked equally well and were free, consumers were told. The difference? One was approved by the FDA in 2009, the other in 2001.

This time, 53 percent chose the older drug when given a warning about the newer one. The caution said: "As with all new drugs, rare but serious side effects may emerge after the drug is on the market - when larger numbers of people have used the drug."

Fewer people, 34 percent, chose the older - and perhaps safer - drug when they didn't get that warning.

"One of the reasons doctors tend to prescribe newer, expensive drugs is there's a widespread perception that newer is better," said Dr. Michael Steinman of San Francisco VA Medical Center, who wrote a commentary about the study in the journal. "That's sometimes true, but many times it's not true. So much of what doctors learn about new drugs is somehow affected by drug company marketing."

The survey was conducted in 2009 by the Internet research firm Knowledge Networks, and has a margin of sampling error of plus or minus 2.4 percentage points. Participants were recruited using telephone and mail sampling and given free Internet access if they needed it.

Woloshin said simple cautions would help doctors, too, and should be part of drug advertising and labeling. He and co-author Dr. Lisa Schwartz have been working with the FDA to improve its guidance to drug makers on writing labels, he said.

They also are promoting the idea of drug fact boxes, similar to the nutrition fact boxes on packaged foods. The fact boxes, written in plain English, would tell consumers how well a drug works compared to other drugs and include side effects.

Last year's national health care law required the Department of Health and Human Services to report to Congress on the evidence for drug fact boxes. The department's report said it needed at least three more years to study the idea.

Drug fact boxes could help and doctors, Steinman said, and patients can question their doctors about prescriptions. He suggested these questions for starters: "Is this drug recommended by the guidelines for my disease? Is there a drug that's equally effective but has a longer track record of safety? Has this drug been shown to help people like me live longer or feel better?"

More information: Archives: http://www.archinternmed.com

©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

3 /5 (3 votes)  

Rank 3 /5 (3 votes)
Related Stories
Relevant PhysicsForums posts
  • Potential Breakthrough in Seizure Control
    created4 hours ago
  • Popping/Cracked sternum.
    created8 hours ago
  • Which Mental Illness Encompasses This Problem?
    created9 hours ago
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Missouri opts for untested drug for executions

(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee ...

Medications created May 24, 2012 | popularity not rated yet | comments 4

Aspirin may prevent recurrence of deep vein blood clots

(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, ...

Medications created May 23, 2012 | popularity not rated yet | comments 2 | with audio podcast

Patients may receive too much acetaminophen in hospital

(HealthDay) -- Roughly 2.5 percent of admitted hospital patients may receive more than the safe daily cumulative dose of the pain-reliever acetaminophen, best known as Tylenol, on at least one day, according ...

Medications created May 23, 2012 | popularity 1 / 5 (1) | comments 0

New quality standards limiting elemental impurities in medicines announced

As part of its ongoing efforts to help ensure the quality of medicines, the U.S. Pharmacopeial Convention (USP) has announced two new standards related to elemental impurities: General Chapters Elemental Impurities—Limits and ...

Medications created May 23, 2012 | popularity not rated yet | comments 0

Quality standards for heparin further strengthened

To help further secure a safe supply of the widely–used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel ...

Medications created May 23, 2012 | popularity not rated yet | comments 0


Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Tongue analysis software uses ancient Chinese medicine to warn of disease

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.